SK Capital Acquires Majority Stake in French Pharmaceuticals Provider SEQENS.

MANews-(C)2009-2021

Funds advised by Florida-based investment firm SK Capital Partners has acquired a majority shareholding in French pharmaceutical solutions and speciality ingredients companies SEQENS, to strengthen position in global pharmaceutical solutions and speciality ingredients markets, the company said.

Terms of the transaction were not disclosed.

SK Capital is investing alongside several other investors including Bpifrance, the French national investment bank, Nov SantÃ(c), MÃ(c)rieux Equity Partners, Ardian, Eximium and the company's management team.

Concurrent with the acquisition, SEQENS entered a combination with Wavelength Pharmaceuticals, an existing SK Capital portfolio company and manufacturer and developer of active pharmaceutical ingredients.

Prior to the closing, SEQENS divested certain non-core mineral specialties assets, including the sodium bicarbonate, soda ash and sodium silicate production facilities in Laneuveville-devant-Nancy (France), Nogent L'Artaud (France) and Jurong Island (Singapore).

As a result of these transactions, SEQENS is positioned as a stronger and more focussed player in the global pharmaceutical solutions and speciality ingredients markets, with revenues of EUR 1.1 bn, 24 industrial sites, 10 R and D centres and 3,200 employees located across three continents.

The company has a product portfolio of more...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT